Teva- Pharmaceutical Industries Ltd. ADR [NYSE: TEVA] closed the trading session at $18.76.
The stocks have a year to date performance of 79.69 percent and weekly performance of 2.68 percent. The stock has been moved at 41.05 percent over the last six months. The stock has performed 12.54 percent around the most recent 30 days and changed 11.93 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 8.92M shares, TEVA reached to a volume of 3980687 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Teva- Pharmaceutical Industries Ltd. ADR [TEVA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TEVA shares is $21.86 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TEVA stock is a recommendation set at 1.64. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Argus have made an estimate for Teva- Pharmaceutical Industries Ltd. ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 10, 2024. The new note on the price target was released on March 08, 2024, representing the official price target for Teva- Pharmaceutical Industries Ltd. ADR stock. Previously, the target price had yet another raise from $12 to $19, while Piper Sandler kept a Overweight rating on TEVA stock. On January 23, 2024, analysts increased their price target for TEVA shares from 10 to 14.
The Average True Range (ATR) for Teva- Pharmaceutical Industries Ltd. ADR is set at 0.48, with the Price to Sales ratio for TEVA stock in the period of the last 12 months amounting to 1.30. The Price to Book ratio for the last quarter was 3.34, with the Price to Cash per share for the same quarter was set at 1.99. Price to Free Cash Flow for TEVA in the course of the last twelve months was 10.25 with Quick ratio for the last quarter at 0.59.
TEVA stock trade performance evaluation
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.68. With this latest performance, TEVA shares gained by 12.54% in over the last four-week period, additionally plugging by 41.05% over the last 6 months – not to mention a rise of 93.40% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TEVA stock in for the last two-week period is set at 67.47, with the RSI for the last a single of trading hit 73.16, and the three-weeks RSI is set at 64.19 for Teva- Pharmaceutical Industries Ltd. ADR [TEVA]. The present Moving Average for the last 50 days of trading for this stock 17.10, while it was recorded at 18.49 for the last single week of trading, and 13.93 for the last 200 days.
Teva- Pharmaceutical Industries Ltd. ADR [TEVA]: An insightful look at the core fundamentals
Teva- Pharmaceutical Industries Ltd. ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.59 and a Current Ratio set at 0.89.
Earnings per share (EPS) analysis for Teva- Pharmaceutical Industries Ltd. ADR [TEVA] stock
With the latest financial reports released by the company, Teva- Pharmaceutical Industries Ltd. ADR posted 0.6/share EPS, while the average EPS was predicted by analysts to be reported at 0.61/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.01. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TEVA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Teva- Pharmaceutical Industries Ltd. ADR go to 1.60%.
Teva- Pharmaceutical Industries Ltd. ADR [TEVA]: Institutional Ownership
There are presently around $55.38%, or 55.38%% of TEVA stock, in the hands of institutional investors. The top three institutional holders of TEVA stocks are: BLACKROCK INC. with ownership of 42.99 million shares, which is approximately 3.8279%. FMR LLC, holding 41.98 million shares of the stock with an approximate value of $$682.15 million in TEVA stocks shares; and FMR LLC, currently with $$590.36 million in TEVA stock with ownership which is approximately 3.2351%.
